<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1561-3194</journal-id>
<journal-title><![CDATA[Revista de Ciencias Médicas de Pinar del Río]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Ciencias Médicas]]></abbrev-journal-title>
<issn>1561-3194</issn>
<publisher>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1561-31942022000300024</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Avances en la caracterización y el tratamiento del cáncer de mama]]></article-title>
<article-title xml:lang="en"><![CDATA[A step forward in the characterization and treatment of breast cancer]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[de Dios-Hernández]]></surname>
<given-names><![CDATA[Daneilys]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas de Pinar del Río Facultad de Ciencias Médicas &#8220;Dr. Ernesto Che Guevara de la Serna&#8221;. ]]></institution>
<addr-line><![CDATA[Pinar del Río ]]></addr-line>
<country>Cuba.</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>26</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1561-31942022000300024&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1561-31942022000300024&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1561-31942022000300024&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: el cáncer de seno es la patología más frecuente dentro de los carcinomas que ocurren en las féminas. Sucede cuando las células mamarias crecen de forma descontrolada debido al fallo de los mecanismos regulatorios proliferativos. Los tratamientos actuales suponen elevados efectos adversos para la salud de los pacientes y la eficacia en muchos casos, no es la esperada.  Objetivo:  describir los avances en el tratamiento del carcinoma mamario que se basan en una alta actividad biológica, selectividad y baja toxicidad.  Métodos:  a partir de la consulta de las bases de datos Scielo, Pubmed, Springer, Science Direct, Mediagraphic y Redalyc, se obtuvieron los artículos relacionados con la investigación. Los métodos teóricos de análisis y síntesis permitieron el estudio del tema en cuestión, y se seleccionó el 75 % de las publicaciones de los últimos tres años.  Desarrollo: se trabaja en el desarrollo de nuevos fármacos contra el cáncer de mama que incluyen inhibidores del factor de transcripción STAT3, inhibidores PARP poli-ADP-ribosa polimerasa (PARP) y el uso de biomarcardores micro ARN. Las técnicas de acoplamiento molecular han permitido el diseño de inhibidores del receptor a estrógenos y del factor epidérmico de crecimiento humano con valores de energía inferiores a los compuestos naturales.  Conclusiones: el desarrollo de candidatos potenciales pretende la disminución de la toxicidad e invasión del tumor, y aumento de la selectividad y actividad biológica. El diseño de llaves maestras puede ser una opción atractiva contra el cáncer de seno.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  breast cancer is the most frequent pathology within carcinomas occurring in females. It happens when breast cells grow uncontrolled due to failure of proliferative regulatory mechanisms. Current treatments involve high adverse effects for the health of patients and the efficacy in many cases is not as expected.  Objective:  to describe the advances in the treatment of breast carcinoma which are based on high biological activity, selectivity and low toxicity.  Methods:  articles related to the research were taken from SciELO, Pubmed, Springer, ScienceDirect, Mediagraphic and Redalyc databases. Theoretical methods of analysis and synthesis allowed the study of the topic in question, and 75 % of the publications of the last three years were chosen.  Development:  work is currently underway on the development of new drugs against breast cancer including STAT3 transcription factor inhibitors, PARP poly-ADP-ribose polymerase (PARP) inhibitors and the use of micro-RNA biomarkers. Molecular docking techniques have allowed the design of estrogen receptor and human epidermal growth factor inhibitors with lower energy values than natural compounds.  Conclusions:  the development of potential candidates aims at decreasing tumor toxicity and invasiveness as well as increasing selectivity and biological activity. The design of master keys may be an attractive option against breast cancer.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[NEOPLASIAS DE LA MAMA]]></kwd>
<kwd lng="es"><![CDATA[FACTORES DE RIESGO]]></kwd>
<kwd lng="es"><![CDATA[MUJERES]]></kwd>
<kwd lng="es"><![CDATA[GENES]]></kwd>
<kwd lng="en"><![CDATA[BREAST NEOPLASMS]]></kwd>
<kwd lng="en"><![CDATA[RISK FACTORS]]></kwd>
<kwd lng="en"><![CDATA[WOMEN]]></kwd>
<kwd lng="en"><![CDATA[GENES]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramírez Valle]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[García Montesino]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cáncer de mama invasivo según subtipos moleculares en la provincia de Pinar del Río]]></article-title>
<source><![CDATA[Rev Ciencias Médicas]]></source>
<year>2020</year>
<numero>5</numero>
<issue>5</issue>
<page-range>Disponible</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramírez Valle]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[García Montesino]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lores Hechevarria]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Azcuy]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Márquez Hernández]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Histological and immunohistochemistry of invasive breast cancer in Pinar del Río province Cuba]]></article-title>
<source><![CDATA[Rev Ciencias Médicas]]></source>
<year>2019</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>71-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valdés Lara]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[García Espinosa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pedroso Morales]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La rehabilitación del cáncer de mama en Cuba]]></article-title>
<source><![CDATA[Rev Invest. Medicoquir]]></source>
<year>2019</year>
<volume>11</volume>
<numero>^ssupl.1</numero>
<issue>^ssupl.1</issue>
<supplement>supl.1</supplement>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<source><![CDATA[Anuario estadístico 2018]]></source>
<year>2019</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Salud Pública. Dirección de Registros Médicos y Estadísticas de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peña García]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Maceo González]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ávila Céspedes]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Utria Velázquez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Más López]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores de riesgo para padecer cáncer de mama en la población femenina]]></article-title>
<source><![CDATA[Rev Finlay]]></source>
<year>2017</year>
<volume>7</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>283-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Echevarría Lores]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El carcinoma de mama. Caracterización clínico-patológica en un hospital de la atención secundaria pinareña.]]></article-title>
<source><![CDATA[Rev Ciencias Médicas]]></source>
<year>2016</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>75-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raya Pérez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Las bases moleculares del cáncer.]]></article-title>
<source><![CDATA[Acta Universitaria]]></source>
<year>2006</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>40-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biología del cáncer de mama.]]></article-title>
<source><![CDATA[Rev Venez Oncol]]></source>
<year>2016</year>
<volume>28</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>188-200.</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sherr]]></surname>
<given-names><![CDATA[CJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Principles of tumor suppression.]]></article-title>
<source><![CDATA[Rev Cell]]></source>
<year>2004</year>
<volume>116</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>235-246.</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Isakoff]]></surname>
<given-names><![CDATA[SJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triple Negative Breast Cancer: Role of Speci?c Chemotherapy Agents]]></article-title>
<source><![CDATA[Cancer J]]></source>
<year>2010</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>53-61.</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Waks]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Winer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast Cancer Treatment]]></article-title>
<source><![CDATA[A Review. JAMA]]></source>
<year>2019</year>
<volume>321</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>288-300</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Joshi Himanshu]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular oncology of breast cancer]]></article-title>
<source><![CDATA[The Breast]]></source>
<year>2018</year>
<numero>22</numero>
<issue>22</issue>
<page-range>282-307</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Xiao]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of various treatment approaches for treatment efficacy for late stage breast cancer and expression level of TIMP-1 and MMP-9.]]></article-title>
<source><![CDATA[Cancer Biomarkers]]></source>
<year>2018</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Buyse]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rastogi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Geyer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Patocskai]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5]]></article-title>
<source><![CDATA[Clin Breast Cancer]]></source>
<year>2017</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>48-54.</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khosravi Shahi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cabezón Gutiérrez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Custodio Cabello]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies]]></article-title>
<source><![CDATA[Asia Pac J Clin Oncol]]></source>
<year>2018</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>32-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Halil Yildirim]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed Azzawri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Duran]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thymoquinone induces apoptosis via targeting the Bax/BAD and Bcl-2 pathway in breast cancer cells.]]></article-title>
<source><![CDATA[Dicle Tip Dergisi/Dicle Med]]></source>
<year>2019</year>
<volume>46</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>411-7</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Allahverdiyev]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Parlar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Dinparvar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bagirova]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sefik Abamor]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current aspects in treatment of breast cancer based of nanodrug delivery systems and future prospects]]></article-title>
<source><![CDATA[Artificial cells]]></source>
<year>2018</year>
<volume>46</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>S755-62</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Qin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review]]></article-title>
<source><![CDATA[Journal of Experimental and Clinical Cancer Research]]></source>
<year>2019</year>
<volume>38</volume>
<numero>195</numero>
<issue>195</issue>
<page-range>1-16.</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adhami]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Akbar Haghdoost]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Malekpour Afshar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Candidate miRNA in human breast cancer biomarkers: a systematic review]]></article-title>
<source><![CDATA[Breast Cancer]]></source>
<year>2018</year>
<volume>25</volume>
<page-range>198-205</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papadimitriou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mountzios]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Papadimitrioua]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum on syntetic lethality.]]></article-title>
<source><![CDATA[Cancer treatment reviews]]></source>
<year>2018</year>
<volume>67</volume>
<page-range>37-44.</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Márquez Fernández]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Camargo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic potential of omega fatty acids in breast cancer]]></article-title>
<source><![CDATA[Vitae]]></source>
<year>2019</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>23-43</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Cicco]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Catani]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Gasperi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Sibilano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Quaglietta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Savini]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nutrition and Breast Cancer: A Literature Review on Prevention, Treatment and Recurrence.]]></article-title>
<source><![CDATA[Nutrients]]></source>
<year>2019</year>
<volume>11</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1514</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[León Barrios]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Céspedes Quevedo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vinent Céspedes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neutropenia inducida por citostáticos en oncología]]></article-title>
<source><![CDATA[Medisan]]></source>
<year>2017</year>
<volume>21</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>3163-71</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soriano García]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Batista Albuerne]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lima Pérez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[González González]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez Rojas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Luaces Álvarez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación del uso de ácido zoledrónico en pacientes con cáncer de mama metastásico a hueso]]></article-title>
<source><![CDATA[Rev Cubana de Medicina]]></source>
<year>2010</year>
<volume>49</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33-64</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Portelles Cruz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Alberteris]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Sarabia]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sanz Pupo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Oller Pousada]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quimioterapia neoadyuvante en cáncer de mama, localmente avanzado]]></article-title>
<source><![CDATA[Rev CCM]]></source>
<year>2013</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>433-42</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soriano García]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lima Pérez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Batista Albuerne]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[González González]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Manuel Pangui]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación del uso del esquema de paclitaxel con carboplatino en pacientes con cáncer de mama metastásico.]]></article-title>
<source><![CDATA[Revista Cubana de Medicina]]></source>
<year>2009</year>
<volume>48</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1-15</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parvizpour]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Razmara]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pourseif]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Omidi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In silico design of a triple-negative breast cancer vaccine by targeting cancer testis antigens.]]></article-title>
<source><![CDATA[BioImpacts]]></source>
<year>2019</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>45-56.</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Speck Planche]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cordeiro]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fragment-based in silico modeling of multi-target inhibitors against breast cancer-related proteíns.]]></article-title>
<source><![CDATA[Molecular Diversity]]></source>
<year>2017</year>
<volume>21</volume>
<page-range>511-23</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sinha]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Athar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vora]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chhabria]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Jha]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Shrivastava]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Structure-based identification of novel sirtuin inhibitors against triple negative breast cancer: An in silico and in vitro study.]]></article-title>
<source><![CDATA[Rev Int J Biol Macromol]]></source>
<year>2019</year>
<volume>140</volume>
<page-range>454-68</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suryani]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Opik]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Siti]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ida]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Epa]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In silico analysis of formononetin compound as a breast anti cancer.]]></article-title>
<source><![CDATA[Rev Latinoamérica de Hipertensión]]></source>
<year>2018</year>
<volume>13</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>579-83</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
